Literature DB >> 3607326

Antigenic release of paf-acether and beta-glucuronidase from alveolar macrophages of asthmatics.

B Arnoux, M Joseph, M H Simoes, A B Tonnel, P Duroux, A Capron, J Benveniste.   

Abstract

Alveolar macrophages (AM) from control (n = 12) and atopic patients (n = 19, 12 without treatment, 4 treated with theophylline and 3 with theophylline and corticosteroid) were compared for their capacity to release mediators. AM were purified by 2 h adherence and challenged with either ubiquitous allergen, specific sensitizing allergens, anti-IgG or anti-IgE serum. The release of paf-acether, lyso paf-acether and beta-glucuronidase was measured. Paf-acether and its lyso derivative were assayed on washed rabbit platelets. Enzyme and mediator releases were obtained after specific allergenic or anti-IgE serum challenge of AM from untreated atopic patients. No release of paf-acether was detected from AM, from control or treated atopic patients after in vitro immunological challenge, whereas that of lyso paf-acether was greatly reduced in both treated groups. Release was obtained by immunological challenge of AM from control patients after passive sensitization with atopic serum. The release of mediators with bronchoconstriction activity by AM could represent an alternative causal pathway in human asthma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3607326

Source DB:  PubMed          Journal:  Bull Eur Physiopathol Respir        ISSN: 0395-3890


  8 in total

Review 1.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

3.  Effect of platelet activating factor (PAF) on the migration of human lymphocytes.

Authors:  R G McFadden; M A Bishop; A N Caveney; L J Fraher
Journal:  Thorax       Date:  1995-03       Impact factor: 9.139

4.  Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.

Authors:  P Hilliquin; J Natour; J Aissa; P Guinot; S Laoussadi; J Benveniste; C J Menkes; B Arnoux
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

5.  Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation.

Authors:  W S Adamus; H Heuer; C J Meade; G Frey; H M Brecht
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Enhanced responsiveness of ovalbumin-sensitized guinea-pig alveolar macrophages to tachykinins.

Authors:  S Brunelleschi; A Parenti; E Ceni; A Giotti; R Fantozzi
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

7.  Decrease of ciliary beat frequency by platelet activating factor: protective effect of ketotifen.

Authors:  L Kahhak; A Roche; C Dubray; C Arnoux; J Benveniste
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

8.  BN 52021 (a platelet activating factor-receptor antagonist) decreases alveolar macrophage-mediated lung injury in experimental extrinsic allergic alveolitis.

Authors:  J L Pérez-Arellano; T Martín; J M López-Novoa; M L Sánchez; A Montero; A Jiménez
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.